AB0124

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

AB0124 is a serotonin 5-HT 2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT 2A receptor, with no potentiation of the serotonin 5-HT 2B and 5-HT 2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT 2 receptors. AB0124 has been studied in combination with the serotonin 5-HT 2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.

AB0124 is a serotonin 5-HT 2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT 2A receptor, with no potentiation of the serotonin 5-HT 2B and 5-HT 2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT 2 receptors. AB0124 has been studied in combination with the serotonin 5-HT 2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1333756690 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.